Rosiglitazone and Clarithromycin Interaction

Understanding the Rosiglitazone and Clarithromycin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Rosiglitazone belongs to the Thiazolidinedione class and Clarithromycin belongs to the Macrolide Antibiotic class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Clarithromycin slows down the process your body uses to get rid of rosiglitazone, which can cause the drug to build up in your system. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Rosiglitazone has 12 total documented interactions on file in this dataset, and Clarithromycin has 81. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to monitor your blood sugar levels more closely and adjust your medication if needed. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Rosiglitazone or Clarithromycin based on a web page, speak with your prescriber or pharmacist before making any change.